All In Biotech

Drug Trial Radar · NCT02075281

Effect of LAPS-Exendin on Body Weight in Obese Population

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 297 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

297

Actual

Start

Feb 2014

Primary completion

Jan 2015

Study completion Feb 2015

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.

Conditions

  • Obesity

Interventions

  • HM11260CBiological

    Glucagon-like peptide-1 analogue

  • PlaceboBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weight at 20 weeksTime frame: 20 weeks from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanmi pharmaceutical

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.